dpp-4 inhibitors and glp-1 agonists Comparison of receptor The Role of DPP-4 Inhibitors

This reflects the chronic and relapsing nature of obesity

The ability to meet global demand consistently may prove as valuable as clinical superiority in determining market share over the coming years

You can read the abstract of this article at 679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes | Diabetes | American Diabetes Association (diabetesjournals.org)

The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health (UK)

It helps regulate blood sugar, slows stomach emptying, and makes you feel full for longer

Lower Risk of Weight Regain Prevents rebound weight gain when combined with lifestyle changes